Glioblastoma is the most aggressive malignant tumor of the central nervous system with a
low survival rate. The difficulty of obtaining this tumor material represents a major limitation …

Glioblastoma (GBM) is the most common malignant brain tumor in adults, and
immunotherapies and genetic therapies for GBM have evolved dramatically over the past …

Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis.
Currently, treatment methods of GBM are limited with adverse outcomes and low survival …

Background: The expression of long non-coding RNA (lncRNA) can function as diagnostic
and therapeutic biomarker for tumors. This research explores the role of PD-L1-related …

Glioblastoma (GBM) is one of the most prevalent and aggressive central nervous tumors
with high mobility and mortality. The prognosis of patients with GBM is poor. It is therefore …

Glioblastoma (GB) is the most aggressive form of brain cancer in adults, characterized by
poor survival rates and lack of effective therapies. MicroRNAs (miRNAs) are small, non …

Glioblastoma (GBM) is a highly aggressive type of primary brain cancer with a poor
prognosis, and despite intensive research, survival rates have not significantly improved …

Nucleolar and spindle-associated protein 1 (NUSAP1) is a potential molecular marker and
intervention target for glioblastoma (GBM). In this study, we aim to investigate upstream …

Ischemic stroke is one of major causes of disability. In the pathological process of ischemic
stroke, the up-regulation of Ras homolog gene family, member A (RhoA) and its downstream …

Background Glioblastoma (GBM) is the most frequent type of primary brain cancer, having a
median survival of only 15 months. The current standard of care includes a combination of …